Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/3/2017
SIETES contiene 91704 citas

 
 
 1 a 20 de 1399 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
2. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
3. Cita con resumen
Anónimo. Chutes et médicaments. Prescrire 2016;36:825. [Ref.ID 100951]
4. Cita con resumen
Anónimo. Sacubitril + valsartan et insuffisance cardiaque chronique. Prescrire 2016;36:645-50. [Ref.ID 100816]
5. Cita con resumen
Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016:22 de agosto. [Ref.ID 100584]
6.Tiene citas relacionadas Cita con resumen
Cunningham CJ. Research into “real world” older patients is needed. BMJ 2016;353:i3136. [Ref.ID 100379]
7.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
8. Cita con resumen
9.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
10.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
11.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
13. Cita con resumen
McMurray JJV, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM, for the ATHMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016;374:1521-32. [Ref.ID 100244]
14. Cita con resumen
Ekstam AK, Elmståhl S. Do fall-risk-increasing drugs have an impact on mortality in older hip fracture patients? A population-based cohort study. Clinical Interventions in Aging 2016;11:489-96. [Ref.ID 100216]
15. Cita con resumen
Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and renal outcomes of renin–angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Medicine 2016:8 de marzo. [Ref.ID 100213]
16.Enlace a cita original Cita con resumen
González C, Fernández E. Olmesartan, un fàrmac a descartar?. Comptagotes. Butlletí d'actualització terapèutica 2016:1-2. [Ref.ID 100212]
18. Cita con resumen
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. [Ref.ID 100151]
19. Cita con resumen
Feldman AM, Haller JA, DeKosky ST. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 2016;315:25-6. [Ref.ID 100122]
20. Cita con resumen
Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, McMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahími K, Perkovic V, Rodgers A. Effect of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43. [Ref.ID 100094]
Seleccionar todas
 
 1 a 20 de 1399 siguiente >>